The FDA on July 24, 2015 approved KYPROLIS® in combination with REVLIMID® (Lenalidomide) and Dexamethasone for the treatment of patients with relapsed multiple myeloma, who had received one to three prior lines of therapy. KYPROLIS® is a product of Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
Bottom Ad
Advertisement
Subscribe
